Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


GREY:BIOAF - Post by User

Post by Boomskidon Jan 12, 2023 2:00pm
221 Views
Post# 35219051

xB3-004 - Between The Lines

xB3-004 - Between The Lines
In August of 2021, I posted a piece about xB3-004 on my StoxComm website. How much of it can be considered "reading between the lines" and how much of it is carefully considered opinion based on significant and documented research on my part? You be the judge.
 
Although I am not reviving the website, I am posting a link to the piece because of the difficulty in posting it here again with all of the links remaining available.
 
You can find the article about xB3-004 (xB3-IL1-Ra) << here >>
 
So why did Bioasis drop all talk of xB3-004? Do they have some quiet plans for it?
 
Also, here is a link to my disclosure page.
 
jd
<< Previous
Bullboard Posts
Next >>